MARC Record from marc_columbia

LEADER: 05125cam a2200949Mi 4500
001 16637966
005 20220709231350.0
006 m o d
007 cr cn|||||||||
008 180502s2018 enka o 000 0 eng d
035 $a(OCoLC)on1033681465
035 $a(NNC)16637966
040 $aTYFRS$beng$erda$cTYFRS$dOCLCO$dYDX$dOCLCF$dOCLCA$dOCLCQ$dOCLCO$dUKMGB$dNRC$dOCLCO$dOCLCA$dS2H$dUKAHL$dOCLCO
015 $aGBB895832$2bnb
016 7 $a018871131$2Uk
019 $a1085632196$a1149984657
020 $a9780429506970$q(e-book)
020 $a042950697X
020 $a9780429015922
020 $a0429015925
020 $z9781138581043
020 $z1138581046
024 8 $a10.4324/9780429506970$2doi
035 $a(OCoLC)1033681465$z(OCoLC)1085632196$z(OCoLC)1149984657
037 $a9780429015922$bIngram Content Group
050 4 $aRS380 .K36 2018
060 4 $a2018 F-543
060 4 $aQV 736.1
072 7 $aMED002000$2bisacsh
072 7 $aBUS071000$2bisacsh
072 7 $aBUS072000$2bisacsh
082 14 $a[E]
082 04 $aSCBS62
082 04 $a[E]
082 04 $aSCEB036220
082 04 $aSCEB0380
082 04 $aSCME0517
049 $aZCUA
100 1 $aKansal, Ruchin,$eauthor.
245 10 $aRedefining Innovation :$bEmbracing the 80-80 Rule to Ignite Growth in the Biopharmaceutical Industry /$cRuchin Kansal, Jeff Huth.
250 $aFirst edition.
264 1 $aLondon :$bTaylor and Francis,$c2018.
300 $a1 online resource :$btext file, PDF
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
520 2 $a"Most people marvel at the level of innovation demonstrated by the biopharmaceutical industry in bringing new products to the market especially in the past 20 years. However, there is a crisis looming in the industry that should be a concern to all of us who take for granted the constant pace at which new treatments, and increasingly cures, have emerged from the laboratories of current sector incumbents. In the book, we examine the evolution of the biopharmaceutical industry to understand how it became what we term a "unicorn industry" with a unique, US-centered business model that has led to multiple blockbuster products (aka, unicorns) year after year. We explore how past success has created perceived barriers to innovation diversification beyond the chemical or biological-based biopharmaceutical product, and highlight the warning signs of the industrys decline. We define a potential pathway for transforming the industrys business model by broadening the definition, sources, and enablers of innovation beyond the traditional biopharmaceutical product. We introduce and advocate for the 80-80 Rule - "Being 80% confident that you will only be 80% right the first time should feel normal." The 80-80 Rule is a theme that emphasizes speed and willingness to embrace uncertainty and overcome internal barriers to change. It sets the standard for redefining innovation as a platform to reignite growth of the biopharmaceutical industry."--Provided by publisher.
505 0 $aRedefining innovation -- Rise of a unicorn industry -- The unicorn industry loses its wings -- An experiment in challenging the status quo -- Innovation redefined -- Next-generation unicorn industry -- Igniting growth -- Applying "the 80-80 rule" -- Setting up for success -- Finding white spaces -- Developing new ventures -- Becoming adept at partnering -- Afterword.
504 $aIncludes bibliographical references and index.
650 0 $aHealth services administration.
650 0 $aPharmaceutical chemistry.
650 0 $aStrategic planning.
650 0 $aPharmaceutical industry.
650 0 $aPharmacy$xResearch.
650 0 $aOrganizational change.
650 0 $aBiopharmaceutics.
650 12 $aDrug Industry
650 22 $aOrganizational Innovation
650 22 $aInventions
650 22 $aBiopharmaceutics
650 2 $aHealth Services Administration
650 2 $aPatient Care Management$xmethods
650 2 $aPatient Care Management
650 2 $aChemistry, Pharmaceutical
650 6 $aServices de santé$xAdministration.
650 6 $aChimie pharmaceutique.
650 6 $aPlanification stratégique.
650 6 $aIndustrie pharmaceutique.
650 6 $aChangement organisationnel.
650 6 $aBiopharmacie.
650 7 $aBUSINESS & ECONOMICS / Industries / General.$2bisacsh
650 7 $aHealth services administration.$2fast$0(OCoLC)fst00953286
650 7 $aPharmaceutical chemistry.$2fast$0(OCoLC)fst01060115
650 7 $aPharmaceutical industry.$2fast$0(OCoLC)fst01060129
650 7 $aPharmacy$xResearch.$2fast$0(OCoLC)fst01060314
650 7 $aStrategic planning.$2fast$0(OCoLC)fst01134371
655 0 $aElectronic books.
655 4 $aElectronic books.
700 1 $aHuth, Jeff,$eauthor.
776 0 $z9780429015939$z9780429015922$z9780429506970$z9780429015915$z9781138581043
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio16637966$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS